# Aegis Sciences Corporation Aegis Sciences Corporation is an Asset Manager based in Nashville, United States. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Nashville, United States - **Region:** North America - **Address:** Nashville, TN, United States - **Founded:** 1990 - **Assets under management:** Undisclosed - **Website:** aegislabs.com - **LinkedIn:** https://www.linkedin.com/company/aegis-sciences-corporation ## Regulatory record - **Reports private funds:** No ## About David Schwab founded Aegis Sciences Corporation in 1990 as a forensic toxicology laboratory in Nashville, Tennessee. The firm serves clinicians, public health agencies, and athletic programs — providing definitive drug testing that goes beyond standard immunoassay screens to identify specific prescription and designer compounds. This remit places Aegis at the intersection of the opioid crisis response and anti-doping enforcement. Aegis deploys instrumentation and methodology across three core verticals: healthcare testing, sports anti-doping, and biopharma molecular diagnostics. Its healthcare products — including Aegis PainComp for chronic pain monitoring and AcuRise ID for mental health and substance use disorder — test for medication adherence and illicit or non-prescribed substances. The sports testing division, operating out of the Wilma Rudolph Sports Testing Laboratory, screens for performance-enhancing drugs like anabolic steroids, stimulants, and diuretics for clients such as the NCAA and professional leagues. A third segment supports clinical trials and pharmacogenetic testing. Confirmed operational regions cover the United States, with state-level licensure spanning California, New York, Maryland, Pennsylvania, and others. Aegis holds accreditations from the College of American Pathologists and maintains DEA licensing. The firm launched an internal dashboard to track novel psychoactive substances across its national specimen pool, aiming to give public health officials real-time visibility into synthetic drug trends. This analytical infrastructure supports a client base that includes clinicians treating Medicare, Managed Medicaid, and commercially insured populations, as well as workers' compensation programs. Aegis distinguishes itself through specimen-level forensic certainty grafted onto a traditional reference-lab business model. Rather than competing with high-volume clinical labs, it competes on molecular specificity — resolving compounds that standard panels miss, such as designer benzodiazepines and synthetic opioids — a differentiation that aligns with heightened DEA and FDA scrutiny on prescription monitoring. ## Sectors - Healthcare Services ## Questions ### What differentiates Aegis drug testing from a standard lab screen? Aegis performs definitive testing using liquid chromatography–tandem mass spectrometry, which identifies specific molecules rather than drug classes. Standard rapid screens often yield false positives or miss synthetic analogs. This forensic approach is designed to detect designer benzodiazepines, fentanyl variants, and other novel psychoactive substances that immunoassay panels overlook, a capability the firm surfaces in its NPS Insights dashboard. ### Does Aegis test for fentanyl and other synthetic opioids? Yes. The firm has integrated synthetic opioid detection into its standard and specialty panels. Its Novel Psychoactive Substances dashboard publicly tracks regional prevalence of compounds like fentanyl analogs, xylazine, and nitazenes using aggregated data from its specimen volume. Aegis offers this surveillance to support clinician and public health response to the synthetic drug crisis. ### What clinical conditions do Aegis testing panels target? The firm designs panels for pain management, behavioral health, substance use disorder, prenatal care, and chronic disease management. PainComp monitors adherence to prescribed opioid and non-opioid medications, while AcuRise ID provides an objective adherence tool for psychiatric and addiction treatment regimens. Each panel is configured to detect both prescribed substances and common non-prescribed or illicit compounds relevant to that population. ### How does the biopharma division complement Aegis's core testing business? Aegis provides molecular diagnostic services to pharmaceutical and research clients, including clinical trial laboratory support and pharmacogenetic testing. This leverages the same analytical chemistry infrastructure used for healthcare and sports testing, applying it to drug metabolism, dose-response validation, and biomarker analysis. It diversifies the client base away from purely clinical reimbursement models without requiring a separate lab network. ## Related profiles - [Neon DAO](https://altss.com/profile/neon-dao) - [DHM Premier Investments](https://altss.com/profile/dhm-premier-investments) --- Last updated: 2026-07-10T19:10:16.000Z Canonical page: https://altss.com/profile/aegis-sciences-corporation Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology